Koers Xbrane Biopharma AB Nasdaq Stockholm
Aandelen
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- SEK | - |
02/05 | Xbrane Biopharma AB (Publ) benoemt Kristoffer Bissessar tot nieuwe directeur | CI |
22/04 | Transcript : Xbrane Biopharma AB - Special Call |
Omzet 2024 * | 344 mln. 31,75 mln. 29,5 mln. | Omzet 2025 * | 680 mln. 62,87 mln. 58,4 mln. | Marktkapitalisatie | 311 mln. 28,76 mln. 26,72 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -186 mln. -17,19 mln. -15,97 mln. | Nettowinst (verlies) 2025 * | 104 mln. 9,61 mln. 8,93 mln. | EV/omzet 2024 * | 0,82 x |
Nettoliquiditeiten 2024 * | 28,17 mln. 2,6 mln. 2,42 mln. | Nettoschuld 2025 * | 116 mln. 10,7 mln. 9,94 mln. | EV/omzet 2025 * | 0,63 x |
K/w-verhouding 2024 * |
-1,51
x | K/w-verhouding 2025 * |
4,25
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 89,26% |
Recentste transcriptie over Xbrane Biopharma AB
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 01-01-15 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 11-01-21 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 09-10-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 67 | 01-01-15 | |
Director/Board Member | 70 | 01-01-15 | |
Director/Board Member | 53 | 01-01-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+22,81% | 47,9 mld. | |
+46,56% | 41,42 mld. | |
-1,88% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+11,33% | 25,55 mld. | |
-21,00% | 19,27 mld. | |
-1,43% | 12,15 mld. | |
+30,73% | 12,14 mld. | |
-0,48% | 11,99 mld. |